Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time!

Expert Opin Pharmacother. 2024 Feb;25(2):123-126. doi: 10.1080/14656566.2024.2312239. Epub 2024 Jan 30.
No abstract available

Keywords: MACE; MAFLD; cardiovascular risk; pharmacotherapy.

Publication types

  • Editorial

MeSH terms

  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Heart Disease Risk Factors
  • Humans
  • Non-alcoholic Fatty Liver Disease* / complications
  • Risk Factors